BriaCell Therapeutics Corp. (BCTXL) Stock Analysis

What BriaCell Therapeutics Corp. does

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Key metrics

ETFs linked to BCTXL

Broad-market and Healthcare sector ETFs an investor holding BriaCell Therapeutics Corp. is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how BCTXL fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for BriaCell Therapeutics Corp.?

BriaCell Therapeutics Corp. trades under the ticker BCTXL on NASDAQ.

Which exchange is BCTXL listed on?

BCTXL is listed on NASDAQ.

What sector does BriaCell Therapeutics Corp. operate in?

BriaCell Therapeutics Corp. is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze BCTXL in a portfolio?

PortView shows BCTXL's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.